World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
105
Citations
49816
World Ranking
6696
National Ranking
3536

Overview

Andrew D. Zelenetz is affiliated with the Memorial Sloan Kettering Cancer Center in the United States. Their research activity is centered primarily within the field of Medicine, encompassing 481 publications. The subfields of study most represented in their work include Pathology and Forensic Medicine, Genetics, Oncology, Pulmonary and Respiratory Medicine, and Molecular Biology.

The main topics addressed in their research focus on Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, and CAR-T cell therapy research. Other areas of work include Viral-associated cancers and disorders, CNS Lymphoma Diagnosis and Treatment, Lung Cancer Treatments and Mutations, and Ovarian cancer diagnosis and treatment.

Frequent co-authors collaborating with Andrew D. Zelenetz include Gilles Salles, Paul A. Hamlin, Ariela Noy, Anita Kumar, and Lorenzo Falchi. These collaborations signify ongoing teamwork in related research domains.

The scientist has published extensively in a range of medical and oncological journals. The most frequent publication venues are Blood, Hematological Oncology, Journal of Clinical Oncology, Blood Advances, and Leukemia & lymphoma/Leukemia and lymphoma.

Some recent papers authored or co-authored by Andrew D. Zelenetz include:

  • The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee (2022, Blood)
  • Outcomes of COVID-19 in patients with CLL: a multicenter international experience (2020, Blood)
  • Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups (2020, Blood Cancer Journal)
  • Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma (2021, Journal of Clinical Oncology)
  • NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021 (2021, Journal of the National Comprehensive Cancer Network)

Best Publications

  • The 2016 revision of the World Health Organization classification of lymphoid neoplasms

    Steven H. Swerdlow;Elias Campo;Stefano A. Pileri;Nancy Lee Harris

  • Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.

    Richard R. Furman;Jeff P. Sharman;Steven E. Coutre;Bruce D. Cheson

  • Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma

    Roland Schmitz;George W. Wright;Da Wei Huang;Calvin A. Johnson

  • Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project.

    Kenneth R. Carson;Andrew M. Evens;Elizabeth A. Richey;Thomas M. Habermann

  • An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era

    Zheng Zhou;Laurie H. Sehn;Alfred W. Rademaker;Leo I. Gordon

  • Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study

    Carla Casulo;Michelle Byrtek;Keith L. Dawson;Xiaolei Zhou

  • Phase II Clinical Experience With the Novel Proteasome Inhibitor Bortezomib in Patients With Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma

    Owen A. O'Connor;John Wright;Craig Moskowitz;Jamie Muzzy

  • Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas

    M. S. Kaminski;A. D. Zelenetz;O. W. Press;M. Saleh

  • Clinical Experience With Intravenous and Oral Formulations of the Novel Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid in Patients With Advanced Hematologic Malignancies

    Owen A. O'Connor;Mark L. Heaney;Lawrence Schwartz;Stacie Richardson

  • A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model

    Craig H. Moskowitz;Stephen D. Nimer;Andrew D. Zelenetz;Tania Trippett

  • Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma

    Tarun Kewalramani;Andrew D. Zelenetz;Stephen D. Nimer;Carol Portlock

  • Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis.

    Adam M Petrich;Mitul Gandhi;Borko Jovanovic;Jorge J Castillo

  • Non-Hodgkin's Lymphomas

    Andrew D. Zelenetz;Ranjana H. Advani;John C. Byrd;Myron S. Czuczman

  • Multicenter phase II study of iodine-131 tositumomab for chemotherapy- relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas

    Julie Marie Vose;Richard L. Wahl;Mansoor Saleh;Ama Z. Rohatiner

  • Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17).

    Jonathan D. Licht;Christine Chomienne;Andre Goy;Alex Chen

  • Ifosfamide, Carboplatin, and Etoposide: A Highly Effective Cytoreduction and Peripheral-Blood Progenitor-Cell Mobilization Regimen for Transplant-Eligible Patients With Non-Hodgkin's Lymphoma

    Craig H. Moskowitz;Joseph R. Bertino;Jill R. Glassman;Eric E. Hedrick

  • NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.

    Zelenetz Ad;Abramson Js;Advani Rh;Andreadis Cb

  • Risk-Adapted Dose-Dense Immunochemotherapy Determined by Interim FDG-PET in Advanced-Stage Diffuse Large B-Cell Lymphoma

    Craig H. Moskowitz;Heiko Schöder;Julie Teruya-Feldstein;Camelia Sima

  • Follicular Lymphoma in the United States: First Report of the National LymphoCare Study

    Jonathan W. Friedberg;Michael D. Taylor;James R. Cerhan;Christopher R. Flowers

  • Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease.

    David J. Straus;Carol S. Portlock;Jing Qin;Jane Myers

Frequent Co-Authors

Craig H. Moskowitz
Craig H. Moskowitz University of Miami
David J. Straus
David J. Straus Memorial Sloan Kettering Cancer Center
Joachim Yahalom
Joachim Yahalom Memorial Sloan Kettering Cancer Center
Anas Younes
Anas Younes AstraZeneca (United Kingdom)
Jonathan W. Friedberg
Jonathan W. Friedberg University of Rochester
Heiko Schöder
Heiko Schöder Memorial Sloan Kettering Cancer Center
Leo I. Gordon
Leo I. Gordon Northwestern University
Myron S. Czuczman
Myron S. Czuczman Citius Pharmaceuticals, Inc.
Julie M. Vose
Julie M. Vose University of Nebraska Medical Center
Ahmet Dogan
Ahmet Dogan Memorial Sloan Kettering Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a career in medicine can open doors to a variety of related healthcare fields and professional pathways. Many students explore online degrees for flexibility and diverse options.

If you’re interested in shaping healthcare policies or managing medical facilities, a healthcare administration degree can provide the skills needed for leadership roles. For nurses aiming to advance their practice, there are adn to fnp bridge programs offering a streamlined transition from an Associate Degree in Nursing to becoming a Family Nurse Practitioner.

Nutrition is another vital field in healthcare. Pursuing an online bs in nutrition can pave the way for roles in wellness, preventive care, or dietetics. Those aspiring to executive positions in hospital or healthcare system management might consider cahme-accredited online mha programs, which are recognized for high standards in healthcare administration education.

Exploring these alternative degrees and career paths broadens options for students passionate about making a difference in healthcare beyond traditional medical school routes.

Best Scientists Citing Andrew D. Zelenetz

Trending Scientists